Cyclin-dependent kinase 4 and 6 inhibitors have become a novel form of adjuvant therapy for the treatment of advanced or metastatic breast cancer characterised by positive hormone receptors and human epidermal growth factor receptor 2 (HER-2) negative. The gene discussed is NR4A1; the disease is breast carcinoma.